Hemophilia A new drug approved for listing, China's hemophilia drug market continues to grow in size

Source: China Report Network

Hemophilia is a group of hemorrhagic diseases with hereditary coagulopathy. Its common feature is the active thromboplastin-producing disorder, prolonged clotting time, and a tendency to post-traumatic hemorrhage in life. Severe patients may also have spontaneous trauma without obvious trauma. Sexual bleeding.

        Recently, the State Food and Drug Administration announced that the Lemicide monoclonal antibody injection for the treatment of rare diseases has been approved for marketing, and the hemophilia A group will benefit. There are three classifications of hemophilia depending on the type of clotting factor that is lacking in the body:

    1. Hemophilia A (hemophilia A), a factor VIII procoagulant component (VIII: C) deficiency, also known as AGH deficiency, is a sexually associated recessive genetic disease, transmitted by women, males.

        2. Hemophilia B (hemophilia B), that is, factor IX deficiency, also known as PTC deficiency, thromboplastin deficiency, is also a recessive inheritance of sex, the number of cases is less than hemophilia A. However, female transmitters with bleeding symptoms in this type are more common than hemophilia A.

        3. Hemophilia C (hemophilia C), factor XI (FXI) deficiency, also known as PTA deficiency, thromboplastin precursor deficiency. It is a rare hemophilia because it is incompletely inherited by autosomes and can be afflicted by both men and women.

        The incidence of hemophilia A (A) is one in ten thousand, and the incidence of hemophilia B is 1 / 35,000. Patients with hemophilia C are rare. Hemophilia patients are almost male, and women generally do not develop the disease, but can carry the disease gene to cause 50% of the males in the birth. The hemophilia manifestations of type A and type B may be hereditary, and the most common is the deficiency or deficiency of factor VIII leading to hemophilia A.

        According to the calculation of the number of people in China, the number of hemophilia patients in China is estimated to be around 100,000. According to the World Federation of Hemophilia (WFH) survey of hemophilia patients, there are 178,500 people worldwide (the survey covers 91% of the world's population), while only 11,108 people in China are registered. The number of hemophilia patients per 10,000 people in China is only 0.08, compared with about 1 in European developed countries and 0.54 in the United States. Japan and South Korea are also 0.45 in Asia, India is 0.14, and well below the global average of 0.27. Therefore, there is still a big gap in the diagnosis and treatment coverage of hemophilia in China.

Hemophilia drug treatment is mainly for blood coagulation factor and hemophilia to support hemostasis. Clinically used in the treatment of hemophilia, human factor VIII, recombinant human factor VIII, recombinant human factor IX, recombinant human factor VIIa, human prothrombin complex, and hemophilia-supporting drug desmopressin , tranexamic acid, aminocaproic acid, thrombin and antibody immunopharmaceuticals all entered the 2017 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List.

        In the next five years, if there is no policy change, China's clotting factor market will grow rapidly. For example, according to the current market growth rate, China's clotting factor market is expected to exceed RMB 5 billion in 2021.

Source: Guanyan World (FSW)